Fleseriu, Maria <br/><br/>
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Jun 2012 
 - 2039-49 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1945-7197 
<br/><br/><label>Standard No.: </label>10.1210/jc.2011-3350  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antihypertensive Agents--therapeutic use<br/>Blood Glucose--drug effects<br/>Blood Pressure--drug effects<br/>Body Composition--drug effects<br/>Body Weight--drug effects<br/>Cushing Syndrome--complications<br/>Diabetes Mellitus, Type 2--complications<br/>Female<br/>Glucose Intolerance--complications<br/>Hormone Antagonists--administration & dosage<br/>Humans<br/>Hydrocortisone--blood<br/>Hypertension--complications<br/>Male<br/>Middle Aged<br/>Mifepristone--administration & dosage<br/>Quality of Life<br/>Quinolines--blood<br/>Receptors, Glucocorticoid--antagonists & inhibitors<br/>Urea--analogs & derivatives